National Immunisation Program Schedule

Last updated
National Immunisation Program Schedule
SalkatPitt.jpg
Jonas Salk holding two bottles containing the polio vaccine he created in 1955 PD-icon.svg One or more of the preceding sentences incorporates text from this source, which is in the public domain : The photograph is of Jonas Salk, the author of the photograph is The Owl, and the photograph was taken in 1957
Specialty Health and Medicine
UsesThe National Immunisation Program is designed to prevent disease in Australia. The schedule sets out all vaccines available in the program
FrequencyThe immunisations range from birth through to adulthood
OutcomesVaccinations create immunity against harmful pathogens

The Australian National Immunisation Program Schedule sets out the immunisations Australians are given at different stages in their life. [1] The program aims to reduce the number of preventable disease cases in Australia by increasing national immunisation coverage. [1] The program starts for an Australian when they are born. Vaccinations are given at birth, then again when the baby is 2 months, 4 months, 6 months, 12 months and 18 months. The immunisation schedule continues when the child is 4 years old, and then into adolescent years. The program is not compulsory and parents have the choice if they want their child vaccinated.

Contents

Background

The National Immunisation Program was first introduced in Australia in 1997. The program was set up by the Commonwealth, state and territory governments. [2] The most recent update to the National Immunisation Program was effective since 1 April 2019. This was an update from the 2007 schedule, one change including the introduction of meningococcal ACWY vaccination for adolescents. The National Immunisation Program Schedule includes vaccines that are funded for children, adolescents and adults. [3] Additional vaccinations necessary when traveling to particular countries are not included in the program, nor are they funded.

"At September 2019, the national immunisation coverage rates were:

The national coverage rate has increased over the last 10 years, as of 2019. [4]

National Immunisation Program Schedule

Childhood vaccinations

Video: Vaccines are injected using a needle. One or more of the preceding sentences incorporates text from a work in the public domain: stock footage of injection during vaccination / immunisation, the author of the video was Centers for Disease Control and Prevention

Birth [5]

2 weeks (Can be given from 6 weeks of age) [5]

4 months [5]

6 months [5]

12 months [5]

18 months [5]

4 years [5]

Adolescent vaccinations

12 – 13 years [5]

14 – 16 years [5]

Adult vaccinations

15 – 49 years [5]

50 years and over [5]

70 – 79 years [5]


See also

Citations and references

  1. 1 2 Health, Australian Government Department of (2017-10-16). "National Immunisation Program Schedule". Australian Government Department of Health. Retrieved 2020-01-30.
  2. Health, Australian Government Department of (2018-04-20). "National Immunisation Program". Australian Government Department of Health. Retrieved 2020-01-29.
  3. "Immunisation schedules | NCIRS". www.ncirs.org.au. Retrieved 2020-01-30.
  4. 1 2 Health, Australian Government Department of (2017-12-21). "Immunisation coverage rates for all children". Australian Government Department of Health. Retrieved 2020-01-30.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 Health, Australian Government Department of (2017-10-16). "National Immunisation Program Schedule". Australian Government Department of Health. Retrieved 2020-02-10.

Related Research Articles

This is a timeline of the development of prophylactic human vaccines. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became available on the market. Although vaccines exist for the diseases listed below, only smallpox has been eliminated worldwide. The other vaccine-preventable illnesses continue to cause millions of deaths each year. Currently, polio and measles are the targets of active worldwide eradication campaigns.

ATC code J07Vaccines is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup J07 is part of the anatomical group J Antiinfectives for systemic use.

<span class="mw-page-title-main">DPT vaccine</span> Combination vaccine

The DPT vaccine or DTP vaccine is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis, and tetanus. The vaccine components include diphtheria and tetanus toxoids and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.

<span class="mw-page-title-main">Vaccination schedule</span> Series of vaccinations

A vaccination schedule is a series of vaccinations, including the timing of all doses, which may be either recommended or compulsory, depending on the country of residence. A vaccine is an antigenic preparation used to produce active immunity to a disease, in order to prevent or reduce the effects of infection by any natural or "wild" pathogen. Vaccines go through multiple phases of trials to ensure safety and effectiveness.

<span class="mw-page-title-main">Childhood immunizations in the United States</span>

The schedule for childhood immunizations in the United States is published by the Centers for Disease Control and Prevention (CDC). The vaccination schedule is broken down by age: birth to six years of age, seven to eighteen, and adults nineteen and older. Childhood immunizations are key in preventing diseases with epidemic potential.

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

The Expanded Program on Immunization is a World Health Organization program with the goal to make vaccines available to all children.

<span class="mw-page-title-main">Pertussis vaccine</span> Vaccine protecting against whooping cough

Pertussis vaccine is a vaccine that protects against whooping cough (pertussis). There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. The effectiveness of the vaccines appears to decrease by between 2 and 10% per year after vaccination with a more rapid decrease with the acellular vaccines. The vaccine is only available in combination with tetanus and diphtheria vaccines. Pertussis vaccine is estimated to have saved over 500,000 lives in 2002.

A vaccine-preventable disease is an infectious disease for which an effective preventive vaccine exists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death.

A Vaccine Information Statement (VIS) is a document designed by the Centers for Disease Control and Prevention (CDC) to provide information to a patient receiving a vaccine in the United States. The National Childhood Vaccine Injury Act requires that medical professionals provide a VIS to patients before receiving certain vaccinations. The VIS includes information about the vaccine's benefits and risks, a description of the vaccine, indications and contraindications, instructions for patients experiencing an adverse reaction, and additional resources.

<span class="mw-page-title-main">Tetanus vaccine</span> Vaccines used to prevent tetanus

Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence.

Universal Immunisation Programme (UIP) is a vaccination programme launched by the Government of India in 1985. It became a part of Child Survival and Safe Motherhood Programme in 1992 and is currently one of the key areas under the National Health Mission since 2005. The programme now consists of vaccination for 12 diseases- tuberculosis, diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B, rotaviral gastroenteritis, Japanese encephalitis, rubella, pneumonia and Pneumococcal diseases. Hepatitis B and Pneumococcal diseases were added to the UIP in 2007 and 2017 respectively. The cost of all the vaccines are borne entirely by the Government of India and is funded through taxes with a budget of 7,234 crore (US$910 million) in 2022 and the program covers all residents of India, including foreign residents.

The Vaccine Damage Payment is a provision of the welfare state in the United Kingdom that provides a payment of £120,000, as of 2023, for people who can show that they have suffered a vaccine injury.

<span class="mw-page-title-main">Mission Indradhanush</span> Health mission of the government of India

Mission Indradhanush is a health mission of the Government of India. It was launched by Union Health Minister J. P. Nadda on 25 December 2014. The scheme this seeks to drive towards 90% full immunisation coverage of India and sustain the same by year 2022. Vaccination is being provided against eight vaccine-preventable diseases nationally, i.e. Diphtheria, Whooping Cough, Tetanus, Polio, Measles, severe form of Childhood Tuberculosis and Hepatitis B and meningitis & pneumonia caused by Haemophilus influenza type B; and against Rotavirus Diarrhea and Japanese Encephalitis in selected states and districts respectively.

DTaP-IPV/Hib vaccine is a 5-in-1 combination vaccine that protects against diphtheria, tetanus, whooping cough, polio, and Haemophilus influenzae type B.

DTaP-IPV-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated polio vaccine or DTaP-IPV-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B.

<span class="mw-page-title-main">Hexavalent vaccine</span> Single vaccine protecting against six individual diseases

A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.

<span class="mw-page-title-main">The Green Book (immunisation guidance, UK)</span> Book about vaccination

Immunisation against infectious disease, popularly known as The Green Book, provides information on vaccines for vaccine-preventable diseases. It acts as a guide to the UK's vaccination schedule for health professionals and health departments that give vaccines in the United Kingdom.

Trudy Virginia Noller Murphy is an American pediatric infectious diseases physician, public health epidemiologist and vaccinologist. During the 1980s and 1990s, she conducted research at Southwestern Medical School in Dallas, Texas on three bacterial pathogens: Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococcus), and methicillin-resistant Staphylococcus aureus (MRSA). Murphy's studies advanced understanding of how these organisms spread within communities, particularly among children attending day care centers. Her seminal work on Hib vaccines elucidated the effects of introduction of new Hib vaccines on both bacterial carriage and control of invasive Hib disease. Murphy subsequently joined the National Immunization Program at the Centers for Disease Control and Prevention (CDC). where she led multi-disciplinary teams in the Divisions of Epidemiology and Surveillance and The Viral Hepatitis Division. Among her most influential work at CDC was on Rotashield™, which was a newly licensed vaccine designed to prevent severe diarrheal disease caused by rotavirus. Murphy and her colleagues uncovered that the vaccine increased the risk of acute bowel obstruction (intussusception). This finding prompted suspension of the national recommendation to vaccinate children with Rotashield, and led the manufacturer to withdraw the vaccine from the market. For this work Murphy received the United States Department of Health and Human Services Secretary's Award for Distinguished Service in 2000, and the publication describing this work was recognized in 2002 by the Charles C. Shepard Science Award from the Centers for Disease Control and Prevention.